Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ILX651 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ILX651 | DRUG | - |
Inclusion Criteria: * Histologically confirmed locally advanced or metastatic NSCLC previously treated with 2 prior chemotherapy regimens (not including prior adjuvant therapy for stage I or II disease). * Disease recurrence or progression after prior therapy with a platinum-based and a taxane-base...
ILX651 is an investigational small molecule being studied for the treatment of hormone-refractory prostate cancer, melanoma, and non-small-cell lung carcinoma. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
ILX651 is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi has sponsored clinical trials of ILX651 in patients with various types of cancer.
ILX651 is in Phase 2 clinical development. It has completed Phase 2 trials for melanoma, non-small-cell lung carcinoma, and hormone-refractory prostate cancer. The drug is investigational and has not been approved for any use.
ILX651 has been studied in three completed Phase 2 trials: NCT00068211 for melanoma, NCT00078455 for non-small-cell lung carcinoma, and NCT00082134 for hormone-refractory prostate cancer. These trials were conducted in the United States.
ILX651 is also known by the name ILX-651, and it is sometimes referred to as tasidotin. These names refer to the same investigational drug being developed by Sanofi for cancer treatment.